Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascend Wellness Holdings, Inc. stock logo
AAWH
Ascend Wellness
$0.33
-3.5%
$0.34
$0.26
$1.23
$67.98M1.01115,683 shs24,286 shs
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
$3.94
-1.1%
$3.84
$1.77
$10.00
$268.25M0.58826,933 shs313,955 shs
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
$24.12
+1.2%
$23.29
$6.20
$29.27
$266.77M-0.11130,255 shs40,233 shs
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
$7.24
-0.5%
$7.88
$6.59
$21.79
$274.57M-0.11134,154 shs66,446 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascend Wellness Holdings, Inc. stock logo
AAWH
Ascend Wellness
0.00%+7.26%+3.91%+3.94%-60.88%
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
0.00%+1.16%+0.64%+35.22%+116.21%
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
0.00%+9.24%-5.04%+20.18%+2,411,999,900.00%
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
0.00%+4.70%-13.04%-11.66%-48.80%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ascend Wellness Holdings, Inc. stock logo
AAWH
Ascend Wellness
1.2429 of 5 stars
0.03.00.00.02.21.71.3
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
2.4595 of 5 stars
3.51.00.00.01.63.30.6
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
3.3999 of 5 stars
3.60.00.00.02.84.20.6
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
3.4947 of 5 stars
3.62.00.00.02.32.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascend Wellness Holdings, Inc. stock logo
AAWH
Ascend Wellness
4.00
Strong BuyN/AN/A
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
3.00
Buy$15.00281.19% Upside
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
3.13
Buy$46.2991.90% Upside
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
3.25
Buy$25.67254.76% Upside

Current Analyst Ratings Breakdown

Latest AAWH, TRDA, PVLA, and CRVS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$12.00 ➝ $11.00
5/20/2025
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
5/16/2025
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$53.00 ➝ $52.00
5/9/2025
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$15.00 ➝ $17.00
4/30/2025
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
4/9/2025
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$50.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascend Wellness Holdings, Inc. stock logo
AAWH
Ascend Wellness
$518.59M0.13$0.05 per share6.64$0.69 per share0.48
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/AN/AN/A$0.51 per shareN/A
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
$42.81M6.23N/AN/A$5.58 per share4.32
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
$210.78M1.30$1.59 per share4.56$11.46 per share0.63
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascend Wellness Holdings, Inc. stock logo
AAWH
Ascend Wellness
-$48.21M-$0.40N/AN/AN/A-15.47%-72.18%-9.55%N/A
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$62.29M-$0.98N/AN/AN/AN/A-24.04%-13.90%8/5/2025 (Estimated)
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
-$17.43M-$12.10N/AN/AN/AN/A-60.29%-43.30%8/13/2025 (Estimated)
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
$65.63M$0.818.93N/AN/A14.39%5.84%4.61%8/12/2025 (Estimated)

Latest AAWH, TRDA, PVLA, and CRVS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
-$3.40-$0.74+$2.66-$0.74N/AN/A
5/8/2025Q1 2025
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$0.13-$0.13N/A-$0.13N/AN/A
5/8/2025Q1 2025
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
-$0.78-$0.42+$0.36-$0.42$10.98 million$8.75 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ascend Wellness Holdings, Inc. stock logo
AAWH
Ascend Wellness
N/AN/AN/AN/AN/A
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/AN/AN/AN/A
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
N/AN/AN/AN/AN/A
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascend Wellness Holdings, Inc. stock logo
AAWH
Ascend Wellness
2.61
1.47
0.80
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/A
4.90
4.90
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
N/A
8.84
8.84
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
N/A
21.88
21.88

Institutional Ownership

CompanyInstitutional Ownership
Ascend Wellness Holdings, Inc. stock logo
AAWH
Ascend Wellness
17.31%
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
46.64%
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
40.11%
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
86.39%

Insider Ownership

CompanyInsider Ownership
Ascend Wellness Holdings, Inc. stock logo
AAWH
Ascend Wellness
22.38%
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
31.30%
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
20.50%
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
7.59%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascend Wellness Holdings, Inc. stock logo
AAWH
Ascend Wellness
2,300204.44 million166.44 millionNot Optionable
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
3068.17 million46.83 millionOptionable
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
N/A11.06 million8.79 millionN/A
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
11037.95 million35.07 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascend Wellness stock logo

Ascend Wellness OTC:AAWH

$0.33 -0.01 (-3.46%)
As of 07/3/2025 12:55 PM Eastern

Ascend Wellness Holdings, Inc. engages in the cultivation, manufacture, and distribution of cannabis consumer packaged goods in the United States. The company offers flower, pre-rolls, concentrates, vapes, edibles, tinctures, and other cannabis-related products under the Common Goods, SimplyHerb, Ozone, Ozone Reserve, Royale, Tunnel Vision, Miss Grass, Lowell Smokes, Edie Parker, 1906, and AiroPro brands. It also owns, operates, and manages cannabis cultivation facilities and dispensaries. The company sells its products through company-owned retail stores and third-party licensed retail cannabis stores. Ascend Wellness Holdings, Inc. was incorporated in 2018 and is headquartered in New York, New York.

Corvus Pharmaceuticals stock logo

Corvus Pharmaceuticals NASDAQ:CRVS

$3.94 -0.05 (-1.13%)
Closing price 07/3/2025 02:54 PM Eastern
Extended Trading
$3.96 +0.02 (+0.51%)
As of 08:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Palvella Therapeutics stock logo

Palvella Therapeutics NASDAQ:PVLA

$24.12 +0.29 (+1.22%)
As of 07/3/2025 01:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

Entrada Therapeutics stock logo

Entrada Therapeutics NASDAQ:TRDA

$7.24 -0.04 (-0.48%)
Closing price 07/3/2025 03:52 PM Eastern
Extended Trading
$7.18 -0.06 (-0.76%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.